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INFLUENCES ON INNOVATION:
EXTRAPOLATIONS TO BIOMEDICAL TECHNOLOGY
Edward B. Roberts
PERSPECTIVES ON INNOVATION
The process of innovation takes into account ali steps leading to the
generation and initial utilization of a new or improved invention. In the
biomedical area an "invention" might relate to a product, a manufacutring
process, or a clinical practice. Innovation requires invention plus ex-
ploitation, which comprises such activities as the evaluation of the techno-
logy; the focusing of technological development efforts toward particular
objectives; the transfer of research results; and the eventual broad-based
utilization, dissemination, and diffusion of research outcomes. All of these
activities are potential areas of managerial or policy concern for enhancing
the rate of outcomes derived from technological innovation. This chapter
summarizes the existing empirical literature on the factors influencing
successful innovation and extrapolates where possible to the biomedical field.
Innovations can be classified into the following overlapping set of
typologies:
Products vs. processes vs. practices
Radical developments vs. incremental changes
New items vs. modifications of existing items
Industrial goods vs. consumer goods
Services
The typologies are a potentially useful approach for analyzing the influences
on innovation. But unfortunately, most empirical work on innovation is out-
side the biomedical arena, on technologies that have been developed in other
fields. Historical investigator bias has led to little research being
carried out on the processes that affect the development of biomedical tech-
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monary advances is a welcome exception to this pattern, embodying major
and substantive empirical work on biomedical development processes. (The
TRACES study (IITRI, 1968) contains some relevant cases as well, but consists
of a biased self-serving sample, thereby lacking objective outcomes.) Conse-
quently , to focus on successful biomedical innovation demands the combina-
tion of empiricism largely from nonbiomedical fields with speculation on
the transferability of ideas across to the biomedical area. Unfortunately,
this lack of systematic empirical understanding restricts the basis on
which either biomedical research programs or policy formation relating to
biomedical research and technology can be advanced.
For example, different factors must affect product innovation--such as
in clinical devices or drug entities--than innovation in clinical practice--
for example, surgical technique or diagnostic approach or therapeutic regimen.
Yet the latter area has not received even cursory attention from empirical
researchers. Studies of technological developments in nonbiomedical areas
indicate that incremental changes rather than radical innovations dominate.
Nevertheless, other than the Comroe-Dripps study, the few innovation studies
in the biomedical area have generally taken anecdotal evidence from radical
developments and have attempted to draw broad-based policy conclusions about
the handling of technology development overall(IITRI, 1968; Battelle, 1973).
Such a practice contributes to an erroneous impression that productive bio-
medical innovation needs to be the same as making a major breakthrough or
winning a Nobel prize.
Studies of technological developments in nonbiomedical areas indicate
that incremental rather than radical innovations dominate research and de-
velopmental outcomes. Research has also been carried out on technological
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efforts resulting in new items or new practices versus modifications and
improvements of old practices. Again, modification and upgrading activities
seem to dominate most fields of endeavor in contrast with the creation of
new entities. Differences in innovation patterns also have been found be-
tween industrial and consumer goods. Medical devices and prescription drugs
fall into the general category of being called "industrial goods"--products
that are turned over to professionals for further use rather than being sold
over-the-counter directly to the consumer. Finally, few meaningful empirical
studies of innovation activities have been conducted in the area of service
delivery, generally, and none specifically of medical services. Thus, an
attempt to understand what influences the development of technology-based
innovation, with empirical evidence as the basis, suffers great weaknesses
from lack of data, especially in regard to biomedical technology.
MAJOR INFLUENCES ON INNOVATION
The identifiable influences on innovation can be clustered into four
groupings: (1) staffing--the kinds of people involved and the nature of the
contribution each kind makes to technological development; (2) structure--
issues affecting developmental linkages and development effectiveness; (3)
strategic--questions on organizational roles, priorities, resources that
affect innovation; and (4) supporting systems--planning, control, and in-
formation analysis techniques helpful to organizations trying to develop
technology effectively. This chapter presents tentative conclusions about
the first three groupings, drawn largely from empirical studies performed
outside the biomedical field, and poses questions as to whether these con-
clusions can be extrapolated appropriately to technological development in
the biomedical area. Supporting systems for innovation are not discussed
in this chapter as the objective research on this topic is essentially non-
existent. Unanswered questions should become part of an explicit agenda for
further research on the biomedical innovation process.
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Staffing
A variety of studies in other fields suggest that five types of key
staff people have critical roles in achieving successful innovation (Roberts
and Fusfeld, 1980). First are the idea generators, the creative contributors
often referred to by those involved in innovating and by the literature (Pelz
and Andrews, 1966; Andrews, 1981). Empirical research points out the signi-
ficant differences between "idea-havers" and "idea-exploiters"--those who come
up with ideas and those who do something with the ideas they have generated.
These differences are now documented in studies of university laboratories and
academic departments as well as in industry, and suggest the second key role in
innovation that is played by entrepreneurs, called "product champions" n some
empirical studies. These people advocate and push for change and innovation;
they take ideas and attempt to get them adopted in organizations (Roberts, 1968).
The biomedical area has a significant number of entrepreneurs, although the term
"entrepreneur" tends to be repugnant in academic medical circles and is usually
a perjorative label, In industry, however, it is not perjorative; indeed, in
the perspective of economic history, Schumpeter (1934) has defined the entre-
preneur as "the engine of economic growth and development". The third necessary
contributor to development is the program manager, sometimes regarded as the
"business innovator", the person who handles the supportive functions of plan-
ning, scheduling, business, and finance relating to the development activities
of technical colleagues (Marquis and Rubin, 1966). Gatekeepers, or special
communicators, play the fourth role by being the links who bring information
messages from outside sources to the inside world of developmental activities.
These human bridges join technical, market, and manufacturing sources of inform-
ation to the potential users of the information (Allen, 1977; Rhoades et al.,
1978). In the medical area, Coleman, Katz, and Menzel (1966) identified gate-
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keepers as critical to the diffusion of new drug entities throughout the
medical community. And finally, empirical studies of technological develop-
ment identify the role of the sponsor, or coach, the more senior person who
is neither carrying out the research itself nor is directly championing the
change, but who is providing junior people with the encouragement, support,
facilitation, and help in "bootlegging" the resources necessary to move
technological advances forward in an organization (Roberts, 1968, p. 252).
Idea Generators vs. Entrepreneurs. Research data are presented here to
illustrate influences of entrepreneurs on development, the references cited
previously illustrating the extensive empirical research on other key staffing
roles. One study of two major MIT laboratories indicates the distinction be-
tween having ideas and exploiting ideas (Peters and Roberts, 1969). Table 1
shows that 49% of the laboratory scientists and engineers claimed to have ideas
that lay outside the major area of interest of the laboratory and which had
commercial implications. However, only 33% of those who claimed such ideas
attempted to do anything whatsoever with their ideas, even given the widest
range of choices for claiming action. Fully two-thirds of these academically
employed scientists and engineers wholly ignored what they claimed to be a
significant development.
The same kinds of behavior were assessed in three major MIT academic
departments (Roberts and Peters, 1981) (Table 2). Of 66 faculty members
statistically distributed to include all major ranks, 47% claimed ideas that
they felt had commercial merit but had done nothing whatsoever about those
ideas; they had not even tried to publish them. Furthermore, only 38% of
the 66 had undertaken strong efforts to move their ideas forward to the point
of use. A study underway is trying to replicate this research among several
samples of academic c illicians to better explain the patterns of idea gcncr-
ation and idea exploitation in that community (Finkelstein et al., 1981).
The faculty person who tries to move an idea forward is different be-
haviorally and sociologically from colleagues who have ideas but do essent-
ially nothing with those ideas. Certain factors of family background, per-
sonal persistence, and a drive for tangible outcomes characterize entrepreneurs
whose actions may account for the innovations achieved (Roberts and Wainer, 1971).
U.S. research is bolstered by U.K. findings that successful, innovative firms
have someone who plays the role of "product champion", whereas firms that fail
do not (Rothwell et al., 1974). Those among the MIT faculty who undertook ex-
ploitative behaviors had characteristics that have been well-documented in
previous studies of entrepreneurs: being first-born children, in this case,
sons; writing a book; obtaining a patent; understanding the financial community;
and being aware of sources of financial support. Most faculty members did
not have these entrepreneurial characteristics.
STRUCTURE
Three structural issues in organizations influence innovation: (1) re-
lationships to sources that motivate the initiation of innovative activity,
(2) relationships to sources of effective technical solutions, and (3) re-
lationships to channels for successful exploitation. The answers to questions
posed here frequently lie in the structural relationships between an organi-
zation that is developing a technology and other linked or supporting organi-
zations with which it is working.
Ill
-7-
Sources Motivating Innovative Activities
Multiple sources are identified as motivating the initiation of success-
ful technological development efforts. The literature reveals extensive con-
troversy among empiricists who divide themselves between the "technology-push"
theory and the "market-demand" or "need pull" theory of innovation (Mowery and
Rosenberg, 1979). The former believe that pushing technology where technological
opportunism seems to exist will eventually result in significant technological
development. The latter believe that factors of mission, need, or demand domi-
nate in motivating those activities which eventually produce most successful
technological developments. The Comroe-Dripps study (1977) was in part initiated
in order to provide evidence for the technology-push theory in explaining the
development of biomedical technology. Comroe-Dripps' results did supply some
reasonable basis for questioning whether studies in other fields apply to bio-
medical technology. Other theories of motivation also merit research, however.
For example, I believe that potential users of an innovation have great but
largely undocumented importance in contributing to biomedical innovation.
Finally, of coprse, the regulatory role needs to be taken into account. Some
suggest that regulation stimulates innovation, but those who have had much to
do with biomedical technology would find the concept of regulatory stimulus
a difficult argument to accept.
Market-Pull vs. Technology-Push. Table 3 lists data from eight studies
carried out in the United States and in Great Britain, with different sampling
approaches from different industries, during different time periods (Utterback,
1974, p. 622). All draw essentially the same conclusion about the sources that
lead to initiation of successful innovation projects: that 60-80% of successful
innovations seem to have been initiated by activities responsive to market-pull,
that is, need-oriented forces. Similarly, recent research on West German
innovations found that 70% of the successes originated from demand-pull factors,
whereas 80% of the failures began with technology-push (Gerstenfeld, 1976).
In further clarifying the role of need-pull, several investigations
have described the nature of the user-producer relationship. The British
Project Sappho found that companies which generated successful innovations
needed less adaptation by users, needed fewer modifications resulting from
user experience after sales, had better understanding of user requirements,
and recognized user problems earlier than did unsuccessful innovators (Rothwell
et al., 1974, p. 265). Several studies focused on the role of explicit customer
requests as an initiator of innovations by manufacturers (Table 4). The results
show a high degree of variation by industry in the importance of this relation-
ship (von Hippel, 1978, p.6).
Comroe and Dripps argued rather that one could not draw any clean and
neat conclusion from the industrial studies that favored the market-pull
theory and that other sources of initiation, like technology-push, were also
important. But the industrial innovation literature clearly supports the
contention that the perception of need that generates response seems to be
the principal motivating factor behind successful innovation. More biomedi-
cally relevant studies are needed to clarify the possible conflict here.
Government Role. What of the government role as a stimulus to biomedical
innovation? Evidence suggests that government regulation sometimes stimulates
successful technological innovation, but primarily in areas of environmental
and safety regulations (Allen et al., 1978; Gerstenfeld, 1977). When the
government pronounces, "You cannot, unless it meets the following specifica-
tions," innovation often suddenly takes place to assure meeting those speci-
fications. But in the area of biomedical innovation, the government role is
not the setting of performance standards but rather one of regulatory inter-
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ference. In drug innovation, where most data exist, the regulatory process
adds enormous costs and time delays to the development of new technologies.
Increasingly, the evidence indicates that abusive regulatory behavior, parti-
cularly in the United States, even denies efficacious entities to clinical
practice. Wardell (1978) traced the drugs introduced in the United States
and Britain during 1972-1976, documenting the negative consequences of U.S.
regulations but also suggesting that some of the regulatory excesses of the
United States are now weakening, bringing the U.S. closer to Great Britain in
a number of areas of market-available drugs. Although regulation may help
in separating good from bad outcomes, the negative influences on develop-
mental quantity, cost, and time make it an inhibitor of biomedical innova-
tion.
Sources of Solutions
Once a program is initiated to solve a need, what are the sources of
technical solutions? The answers come from various sources. Inside and
outside the organization are distinctly different sources of ideas; muchK
research on industrial innovation demonstrates that key technical answers to
major problems come from outside of the organization where the work is under-
way. These studies also show that personal experiences and contacts are
key sources of information whereas the scientific literature yields relatively
little productivity, despite the good intentions of the publications and of
computer-based information retrieval services such as the National Library
of Medicine to provide potentially for better utilization of organized re-
search information. The contrast between original solutions, that is, self-
invented answers, and solutions adoplted or adapted from existing technology
are important to consider, especially in the later stages of an innovation
III
cycle. Finally, in the area of biomedical technology, research has begun
to demonstrate as dominant to innovation the contributions of the user, in
contrast with the producer.
Inside vs. Outside Ideas. The development of a successful innovation
usually requires multiple ideas for solutions to the multiple technical
problems that arise during a project. Several studies point out that for
innovations eventually developed within a firm, the sources of initial tech-
nical ideas divide between inside and outside origins on about a 2:3 basis
(Table 5) (Utterback, 1974, p. 621).
Myers and Marquis (1969, p. 90) studied the sources of information for 567 inno-
vations in five industrial fields with 120 firms. Table 6 lists the sources
of technical solutions for the problems dealt with in these successful com-
mercial innovations. Personal contacts generated a total of 25% of the solu-
tions, and personal training and experience produced an additional 48%,
clearly the dominant sources of technical insights. The Langrish data
(1972, p. 79) (Table 7) also demonstrate that personal contacts, training, and
experience dominate the routes for transferring outside ideas into a firm,
in contrast with the minor role of the literature and other formal sources.
Does this dominance of personal information transfer also hold true for
biomedical innovation? Or does the formal literature convey key scientific
and technical inputs to innovative projects?
Original vs. Adopted Innovations. A stereotype of the source of innova-
tive ideas is the inventor transforming technical and market information into
a creative outcome. An alternative perspective is that some ideas for techno-
logical solutions already exist and the innovating organization merely needs
to adopt or adapt them by slight modification for a new purpose. Few studies
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illuminate this distinction, but the Myers-Marquis data (1969, p. 20) showed
22% of the key innovations to have been adopted or adapted, and the Langrish
U.K. data (1972, p. 79) indicate that 33% of the Queen's Awards were based
on adopted innovations. In examining 567 innovations, Myers and Marquis
(1969, p. 20) found that only 18% of new products in their sample were adopted
whereas 32% of the successful product modifications were adoptions. Reanalyz-
ing a portion of the Myers-Marquis data (77 companies, generating several
hundred innovations), Utterback and Abernathy (1975) divided the development
of a technology into three stages. Stage I was the initial stage of a new
field of technology, Stage II its later development, and Stage III the matur-
ation of a technological area. The researchers found adoption to be present
in all stages of development of a new technology, but especially important
and concentrated in the late mature stage (Table 8). One small study (Gerstenfeld
and Wortzel, 1977) showed adoption to be far more significant in Taiwan,
accounting for the bulk of the successes, even to the point of many purchased
turnkey technologies.
These data, however meager, do suggest the importance of adopted and
adapted innovation in industrial innovation. But how important is this pheno-
menon in the biomedical area? In the medical field, adoption in innovation
for clinical practices may have greater potential than for drugs or devices,
but no studies exist to support this speculation.
User vs. Manufacturer Roles. Increasingly, a special case of adoption ex-
ists when a user creates and implements an innovation for his or her own pur-
poses, followed by a manufacturer's later adoption of the innovation for large-
scale production and distribution. Many ut not all of the studies listed in
Table 9 demonstrate the significlll! con tribtl tiloll; i lte tiser (vol Ililpj)el, 1978,
p. 2). As shown, the first two studies, oth in the plastics indtustry, reveall nio
contributions of users, but in other areas--petroleum and chemical equipment1
Ill
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computers, specialized machinery, aluminum, scientific instruments, and
semiconductor and electronic manufacturing processes--a heavy percentage
of innovations were created by the users of the products or processes
rather than by manufacturers. In each case, a user came up with the success-
ful solution, implemented it first in his or her own organization for per-
sonal use, and made copies available to others on request. Later, a manu-
facturer discovered the successful development and use, fully adopted the
solution, made engineering modifications as needed, and then produced the
innovation in large volume, distributing it to industrial customers or to
the public at large.
In a recent study, von Hippel and Finkelstein (1979, p.31) sought the sources
of innovation for test methods embodied in medical laboratory clinical
analyzers. The study focused on how the design of a physical piece of
equipment encourages or discourages scientific manipulation and experiment-
ation, and eventually further contributes to the process of innovation.
The test methods and origins of the DuPont clinical analyzer and the Tech-
nicon machine were studied (Table 10). For the Technicon SMAC, of the 20
most significant test methods used, 14 were successfully developed and
initially implemented by users of the equipment. Another method was de-
veloped by a reagent manufacturer, a firm supplying chemicals for use with
the Technicon equipment. Only 4 of the 20 test method innovations in the
Technicon SMAC were generated by Technicon itself. One more method is in
question because there were multiple sources of contribution. In contrast,
all of the 18 test methods that constitute the principal utilization of the
DuPont clinical analyzer were developed by DuPont itself--no contributions
by the users. No other evidence is available to establish whether users
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or manufacturers are the dominant sources of innovation of biomedical tools
and devices. I perceive the role of the manufacturer of biomedical devices
as primarily one of adoption and broad-based distribution, not of initial
generation of the ideas nor of initial successful solution of the problems
involved in those ideas.
Channels For Exploitation
Other structural considerations for research are the linkages for trans-
ferring the results of a successful technical development out of the innovat-
ing organization to the outside where they can begin to have impact oil others.
This stage precedes significant external diffusion. The first movement
toward use and implementation generally takes place on a pilot or trial basis,
especially in medicine, before evidence accumulates that might induce wide-
spread diffusion and dissemination.
Effective linkages are needed between research laboratories and product-
line departments in such organizations as pharmaceutical companies. Effect-
ive linkages are needed between universities and industry if the university
is to be a significant source of original technological development in the
biomedical field. Yet no empirical research meaningfully indicates which
patterns of transfer presently dominate or which channels might be more effect-
ive than others. Apparently, with few exceptions (Chemical Week, 1979),effective
linkages do not exist between universities and medical schools and between
universities and the industries that eventually must transfer the product
results of biomedical technological development. The appropriate struct-
uring of such linkages is a controversial issue, now being tackled in in-
creasing numbers of sites. Theoretically, many different kinds of bridges--
procedural, human, and organizational--can be used for technology transfer,
IIIll
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but existing evidence of what occurs is not broad-based (Roberts, 1979) and
not without conflict. For example, recent studies by Young (1981) have
questioned the effectiveness of clinical trials as a mechanism for trans-
ferring research results into broad-based clinical practice. But Levy and
Sondik (1981) have evidenced support of the utility of clinical trials as a
transfer mechanism. Mechanisms for improving the utilization of research
results need major empirical investigation (Roberts and Frohman, 1978),espec-
ially with respect to biomedical innovation.
STRATEGY
In the third cluster of influences on the development of technology are
strategy issues: How does the stage of technology affect the pace and the
nature of technological innovation? Who does the technological innovation?
Is successful innovation done more by large companies, by small companies,
by individual inventors? Is it done more in universities, in industry, or
in government laboratories? Is it done more by outsiders to a given in-
dustry? (Schon, 1973) How much technological change is embodied in significant
innovations? How costly is the process of technological development? What
is the role of patents and trade secrets in these areas? Answers to these
questions in the area of biomedical innovation should provide important found-
ations for corporate and government strategic policy development. All attempts
to formulate policy, to regulate, or to influence emerging or existing tech-
nologies are based at least implicitly on the answers to these and other stra-
tegy questions; yet, again, little empirical research exists in any of these
areas.
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Technology Stage and Innovation
The changing stages along the life-cycle of a technology suggest differ-
ent strategies in terms of the nature, direction and frequency of product and
process innovation. As shown in Table 11, the Utterback-Abernathy analysis (1!75,
p. 649) of Myers-Marquis data reveals considerable differences in patterns of
success in three stages. The earliest phase of a new technology is dom-
inated by product innovation, with little change in manufacturing process.
A rapid decline occurs in the degree of product emphasis in innovative act-
ivity as the technology progresses, with dramatic growth occurring in pro-
cess orientation. Do similar changes occur in pharmaceutical or biomedical
device technology?
Identity of Innovator
An often cited but controversial finding is that individual inventors
and small firms are principal contributors to product and even process inno-
vation, particularly of radical innovation and especially in the early stages.
Data from large-scale industries (Table 12) do indicate rather surprisingly
that small companies and individual inventors tend to dominate in the gener-
ation of key innovations (Enos, 1962; Hamberg, 1963, 1966; Jewkes et al,,
1958; Peck, 1962). Comparable data are not available on medical innovation.
The data become more interesting when examined in regard to the size of
the innovative sources as a function of the stage of technological develop-
ment (Utterback and Abernathy, 1975, pp, 654 and 656). Most companies listed
in Table 13 as "unclassified" are in fact privately-owned small companies who
would not release their sales data, ut are for the most part under $10
million in sales, Combining these "unclassifieds" with those certified as
"small" (<$10 million) demonstrates clearly that small companies are the
principal contributors to major product and process change in Stage I
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of a new technology. By the time a technology gets to Stages II
and especially III, the mature stage of a technology, the role of small com-
panies no longer is dominant though still important. Instead, large compan-
ies (over $100 million in sales) tend to dominate. Precisely the same pattern
appears to be taking place in biogenetic technology; small companies are
rapidly becoming the dominant contributors to innovation in this new field.
Again, systematic studies are needed on the role of the small firm and the
individual inventor in bringing new technologies to fruition in the biomedical
area.
And what of the role of the university in this process? In most indus-
trial fields, the nonprofit sector contributes infrequently to innovation,
though occasionally with fundamental importance. Yet universities, medical
schools, and hospitals appear to be potentially of critical importance in
biomedical innovation. For example, the von Hippel and Finkelstein study
(1979, p. 32) found that nonprofit organizations were the sources of 18 out of 20
manual clinical test methods adapted to and automated on the Technicon SMAC.
The potential consequences for corporate and governmental policy of an im-
portant university role in biomedical innovation require careful study.
Embodied Technological Change
The degree of technological change embodied in a successful innovation
is also an important question for speculation. The Utterback-Abernathy (1975, p. 651)
analysis of the data on 77 companies indicates that 45% of the successful
innovations embodied major invention during Stage I. But in Stage III, when
a technology has been well-established and well-accepted, only 19% of those
innovative successes embodied invention to a meaningful extent (Table 14).
Most of the successes in late stages of a technology involve merely incremental
technological change.
III
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The Hollander data (1965) on DuPont productivity improvements in rayon
plants support the assertion that minimal technological change is embodied
in innovations in the mature stage of an industry. Minor technical changes
accounted for an average of 78% of the net cost reduction in five plants
(Table 15).
This pattern of declining technological change as a function of the
stage of a technology is repeated in costs of innovation. The Utterback-
Abernathy analysis (1975, p. 653) shows that the costs of Stage I innovations
are more or less evenly distributed across cost categories from under $25,000
to more than $1,000,000. On the average, however, Stage I innovations cost
more than the incremental changes with high adoption rates that typify Stage III.
Role of Patents
The data on the role of patents in innovation raise further questions
about the issues of biomedical technology but also suggest possible differ-
ences between biomedical innovation and innovation in other areas. Large
numbers of studies of the role of patents demonstrate, almost without ex-
ception, that patents have little influence on the successful development or
commercialization of technologies (Roberts, 1981). Anecdotal evidence to the con-
trary about the importance of patents in the great successes of Polaroid and Xerox,
the general course of results is that patents are not significant for other
firms and industries. The data in Table 16 demonstrate that the one area-
significantly different from all others is the pharmaceutical industry in
that patent royalties for drugs make a three or four times larger relative
contribution to profits than royalties in other industries (von Hippel, 1979).
Furthermore, the pharmaceutical industry distinguishes itself from other industries
by being concerned about patent availability ill motivating thle i ection, cliir-
acter, and budget of research and development (Taylor and Silberston, 1973).
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SUMMAIRY AND QUEIS'IONS
This chapter has presented a mlcr of major contentions, drawn pri-
marily from data outside of the biomedical arena, about the principal in-
fluences of technology development.
1. Five key staffing roles are vital influences in the develop-
ment of successful technological innovations. The strongest
evidence exists on the need for idea exploiters or entrepre-
neurs (as distinct from merely idea generators). An important
need exists for facilitators of communication (the information
gatekeepers), and a similarly important need for senior manage-
ment helpers (sponsors or coaches).
2. Structure exercises important influences on innovation. Ties to
the market-motivating forces have been found to be primary in
effecting eventual successful technological development. Link-
ages to outside information sources for initial ideas, for tech-
nical solution ideas, and for whole-solution adoption of ideas,
are freqeuntly key to the technological development process, with
personal contacts and experience as the major mechanisms by which
these linkages are effected successfully. Adopted innovation in
general, as well as the special role of the innovative user as a
source of eventually-adopted innovation, need more attention.
Little evidence exists on the differential effectiveness of various
channels of research results transfer, even though this may be the
most critical stage of technological development. Government re-
gulation is seen as largely inhibitive to innovation in the bio-
medical area.
Ill
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3. Different forms of innovation dominate at different stages of
a technology cycle; individual inventors and small firms seem
critical early in development. Patents, seen as insignificant
elsewhere, are important to the pharmaceutical industry, but
this does not necessarily mean that patents are important to
the medical device industry, given the many distinctions among
innovation in the areas of drugs, devices, and clinical practices.
The findings cited here rest largely on empirical studies done primarily
outside of medicine; therefore, some key differences between biomedical re-
search and technology and other fields deserve mention.
1. The uncertainties involved in natural science research and
development are far greater than in the physical sciences,
including problems of biological variability as well as effi-
cacy determination. These problems are far more significant
to biomedicine than to other areas of research and technology.
2. The federal government is an exceptionally high sponsor of bio-
medical technology research but, unlike defense re-
search, is not the direct customer for the implementation of
R&D results. This difference in research utilization has cri-
tical consequences for successful development and use of bio-
medical technology,
3. Relative to any other scientific or technical field, biomedical
technology has the highest degree of academic involvement in
and domination of research.
4. The highest extent of government regulation of product accept-
ability and of product diffusion is encountered in the bio-
medical area.
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5. Strong emotional market factors affect involvement with inno-
vation in and utilization of products, processes, and practices
that influence health and life. This can never be forgotten
when trying to understand what affects successful biomedical
technology development.
A major research program is needed on the influences involved in all
stages of development and dissemination of biomedical innovation. This
program should be supported by the federal government and by foundations.
This program should be initiated promptly, to begin building an empirical
basis for managerial direction, policy formation, and regulatory action in
regard to medical technology.
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Table 1
Individuals Who Had and Exploited Ideas
Whose Scope is Outside the Laboratory
Laboratory N Claimed Such Ideas Attempted to Do Something
# at%
Lincoln 161 72 45 25 35
Instrumentation
Totals
138
299
75
147
54 24
49
Percentage based on those who had such ideas.
Source: Peters and Roberts, 1969.
32
49 33
III
Table 3
Innovations Stimulated by Perceptions
of Market Needs
Study N
% from Market, Mission,
or Production Needs
Baker et al.
Carter/Williams
Goldhar
Langrish et al.
Myers/Marquis
Sherwin/Isenson
Tannenbaum et al.
Utterback
Corporate research
laboratory
British Board of Trade
"Industrial Research"
winners
Queen's Awards
5 Industries
"Hindsight"--weapons
systems
Materials
Instruments
aSource: Redrawn from Utterback, 1974.
bldeas for new products/processes.
CResearch events used in 20 developments.
Author
137
77
73
108 69
84
439
710C
66
78
61
90
75
10
32
Table 4
Manufacturer Innovations Initiated in Response
to Customer Request
Study
Engineering polymers
Plastics additives
Commercially successful
chemical products
Successfully implemented
creative R&D projects on
processes and equipment
% Requested
by CustomerN
5 0
016
17
48
53
62
von Hippel Semiconductor and electronic
assembly manufacturing
processes and equipment
Source: Redrawn from von Hippel, 1978.
Author
Berger
Boyden
Meadows
Peplow
16 38
Table 5
Sources of Ideas for Innovations Developed
Within the Firm
N
% from Outside
the Firm
Langrish et al.
Mueller
Myers/Marquis
Utterback
Queen's Award
DuPont
5 Industries
Instruments
Source: Assembled from data contained in Utterback, 1974.
Author Study
51
25
157
32
65
56
62
66
111
Table 6
Key Source of Information Inputs to
Successful Innovation
Innovator Got the Key Input From: No. of Cases %
Inside the Firm:
Printed Materials 9 2
Personal Contacts 25 4
Own Training and Experience 230 41
Formal Courses 1 0
Experiment or Calculation 40 7
305 54
Outside the Firm:
Printed Materials 33 6
Personal Contacts 120 21
Own Training and Experience 39 7
Formal Courses 8 2
200 36
Multiple Sources 62 11
567 101
Source: Myers and Marquis, 1969.
Table 7
Methods of Transfer of Ideas from Outside for
Successful Innovations
Method
Transfer via person joining the firm
Common knowledge via industrial experience
Common knowledge via education
Commercial agreement (including takeover and sale
of know-how)
Literature (technical, scientific, and patent)
Personal contact in U.K.
Collaboration with supplier
Collaboration with customer
Visits overseas
Passed on by government organization
Conference in U.K.
Consultancy
Total
# of Ideas
20.5
15
9
10.5
9.5
8.5
7
5
6.5
6
2.5
2
102
Source: Langrish et al., 1972.
Table 8
Role of Adoption in Successful Innovation
% Distribution
Stage I Stage II Stage III
Original Innovations
Adopted Innovations
84
16
84
16
49
51
x2 = 72.8, p < 0.0001
Source: Utterback and Abernathy, 1975.
Table 9
Users vs. Manufacturers as Sources
Industrial Innovation
of
% by Source
Industry
Engineering Polymers
N User
6 0
Mfr. Other
100
Plastics Additives
Petroleum Processing, Major
Chemical Processes/Equip.
Computers, 1944-62
Improved Performers
Radical Structures
Lionetta &
von Hippel
Peck
von Hippel
von Hippel
Pultrusion Machinery
,Aluminum Industry
Joining
Finishing
Fabricating
Alloys
Scientific Instruments
First of Type
Major Improvements
Minor Improvements
Semiconductor & Electronic
Assembly Mfg. Equipment
First of Type
Major Improvements
Minor Improvements
Source: Redrawn from von Hppel, 1978.
Author
Berger
Boyden
Enos
Freeman
Knight
16 0
7 43
100
14 43
810
143
18
70
25
33
30
75
67
15
50
48
49
79
33
19
21
18
13 85
52 17
27 33
76 30
39 3
4 100
44 82
63 70
7 100
22 63
20 59
0
18
30
0
21
29
16
12
_ _ _ ___ __ _ _ _ __ __ __
Table 10
Sources of Test Methods for Automated Clinical
Chemistry Analyzers
% by Source
DuPont ACA
Technicon SMAC
N
18
20
User
0
14
Equip.
Mfr.
18
4
Source: Redrawn from von Hippel and Finkelstein, 1979.
Reagent
Mfr.
0
1
Table 11
Patterns of Innovation Along the Technology Cycle
Type of
Innovati on
Product
Component
Process
Stage I
(N=52 firms)
114
39
21
174
66
22
12
100
Stage II
(N=14 firms)
46
8
39
50
9
42
93 101
Stage III
(N=11 firms)
13 21
6 10
44 70
63 101
X2 = 80.7, p<0.0001
Source: Redrawn from Utterback and Abernathy, 1975.
Table 12
Sources of Key Innovations
Major Small Firms
Author Study N Firms and Inventors
Enos Petroleum Refining, 7 0 7
Basic Major Innovations
Hamberg Steel 11 4 7
Hamberg Major Innovations, 27 <1/3 >2/3
1946-1955
Jewkes Major Innovations, 61 <50% >50%
1900-1945
Peck Aluminum, Major 7 1 6
Innovations
Sources: Enos, 1962; Hamberg, 1963, 1966; Jewkes et al., 1958; Peck, 1962.
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1ab1 13
Firm Size and Successful Innovations
Sales
($000,000) Stage I Stage II and III
%/
Unclassified
<10
10-100
>100
12 23
18 34
6 12
16 31
8 32
0 0
2 8
15 60
2
x = 11.2,p<0.01
Source: Assembled from data in Utterback and Abernathy, 1975, pp. 654-656.
__
Table 15
Innovation in DuPont Rayon Plants
Contribution of Minor Technical
Change to % of Net Reduction in
Plant Unit Costs Due to Technical Change
Spruance II-A 83
Spruance I 80
Old Hickory 79
Spruance III 46
Spruance II 100
Source: Drawn from data in Hollander, 1965.
Table 14
Degree of Inve
Requi red
Little
Considerable
"Invention" Ne
X2 - 19.1,
Technological Change in Successful Innovations
% Distri bition
inti on
Stage I Stage II
14 19
41
45!eded
50
31
Stage III
33
48
19
p<O. 001
Source: Utterback and Abernathy, 1975.
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Table 16
Importance of Patents
Wilson
(1971 Royalty Data, U.S.)
Taylor-Silberston
(1968 Royalty Data, U.K.)
Royalties Paid
Industry As % of Sales
Royalties Paid
As % of Sales
Industrial
Activity
Chemicals
Industrial
Drug
Other
Machinery
Electrical
0.244
0.745
0.034
0.051
0.13
0.042
0.635
0.044
0.255
0.182
Chemicals
Basic
Pharmaceutical
Other Finished
and Specialty
Mechanical
Engineering
Electrical
Engineering
Source: Redrawn from von Hippel, 1979.
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I
